Retina Institute Of California Medical Group | |
500 S Anaheim Hills Rd Ste 234, Anaheim, CA 92807-4760 | |
(714) 921-0232 | |
(714) 921-0535 |
Full Name | Retina Institute Of California Medical Group |
---|---|
Type | Facility |
Speciality | Ophthalmology |
Location | 500 S Anaheim Hills Rd Ste 234, Anaheim, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669865747 | NPI | - | NPPES |
1760541569 | Other | CA | GROUP NPI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | A69909 (California) | Secondary |
174400000X | Specialist | A69909 (California) | Secondary |
207W00000X | Ophthalmology | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Retina Institute Of California Medical Group 100 E California Blvd, Pasadena, CA 91105-3205 Ph: (626) 568-8838 | Retina Institute Of California Medical Group 500 S Anaheim Hills Rd Ste 234, Anaheim, CA 92807-4760 Ph: (714) 921-0232 |
News Archive
Long-term follow up with heart bypass patients treated in Veterans Affairs hospitals shows that 85 percent of left internal mammary artery grafts and 61 percent of vein grafts remain open (patent) after 10 years, and that these grafts are more likely to offer long-term success when they are attached to larger arteries on the heart, according to a new study in the Dec. 7, 2004 issue of the Journal of the American College of Cardiology.
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.
Strengthening the link between periodontal and heart disease, researchers at Boston University School of Medicine (BUSM) found they can prevent mice from developing P. gingivalis-accelerated heart disease by immunizing the mice with a vaccine that protects against periodontal disease.
NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.
› Verified 7 days ago